Document is current

Article History

Received: 19 September 2017

Accepted: 1 February 2018

First Online: 13 February 2018

Ethics approval and consent to participate

: Istanbul University Cerrahpasa Medical Faculty Clinical Trial Ethics Committee (Nb:83,045,809/604.01/02-42,378) approved this study. All patients provided written informed consent.

: Not applicable.

: RE: Speaker fees from Novo Nordisk, MSD, AstraZeneca, Boehringer, Sanofi; participation in advisory boards from Novo Nordisk, Sanofi, AstraZeneca.TT: Speaker fees from Gen Pharmaceuticals, Novartis, Lilly, Novo Nordisk, MSD, AstraZeneca, Boehringer, Sanofi, Bilim; participation in advisory boards from Novo Nordisk, Sanofi, Lilly.IS: Speaker fees from Novo Nordisk, MSD, AstraZeneca, Boehringer, Sanofi, Lilly and Novartis; participation in advisory boards from Sanofi, Lilly, Novo Nordisk and AstraZeneca.RS: Speaker fees from Novo Nordisk, MSD, AstraZeneca, Boehringer, Sanofi, Lilly, Novartis; participation in advisory boards from Sanofi, AstraZeneca.AK: Speaker fees from Novo Nordisk, AstraZeneca, Boehringer, Sanofi, Lilly, Novartis; participation in advisory boards from Sanofi, AstraZeneca, NovoNordisk.IY: Speaker fees from Novo Nordisk, AstraZeneca, Boehringer, Sanofi, Novartis, Lilly; participation in advisory boards from Novo Nordisk, Sanofi, AstraZeneca.SC: Employee of Novo Nordisk.NT: Speaker fees from Novo Nordisk, MSD, AstraZeneca, Boehringer, Sanofi, Novartis, Lilly; participation in advisory boards from Novo Nordisk, Sanofi, AstraZeneca.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.